TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sandoz Group Ltd ( (CH:SDZ) ) has shared an update.
Sandoz has launched Wyost® and Jubbonti®, two denosumab biosimilars, in Europe to treat cancer-related bone disease and osteoporosis, expanding access to affordable treatment options for millions. This launch marks a significant step in Sandoz’s growth strategy, reinforcing its leadership in the biosimilars market and its commitment to oncology and immunology. The introduction of these biosimilars is expected to have a substantial impact on European healthcare systems by providing sustainable treatment options and addressing the high burden of cancer and osteoporosis in the region.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF60.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in affordable medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, the company is known for pioneering access to healthcare through its extensive portfolio of approximately 1,300 products. Sandoz employs over 20,000 people worldwide and recorded net sales of USD 10.4 billion in 2024. The company is committed to providing critical and potentially life-changing biologic medicines sustainably and affordably.
YTD Price Performance: 55.42%
Average Trading Volume: 727,624
Technical Sentiment Signal: Buy
Current Market Cap: CHF24.96B
See more data about SDZ stock on TipRanks’ Stock Analysis page.